Bristol Myers Squibb Newswire

Bristol Myers Squibb Newswire

Comprehensive Real-Time News Feed for Bristol Myers Squibb.

Results 1 - 20 of 1,297 in Bristol Myers Squibb

  1. Bristol-Myers reports Q1 profit beat, revenue missRead the original story w/Photo

    54 min ago | MarketWatch

    Earnings for the latest quarter declined to $1.49 billion, or 91 cents per share, from $1.57 billion, or 94 cents per share in the year-earlier period. Adjusted earnings-per-share were 94 cents, compared with the FactSet consensus of 85 cents.

    Comment?

  2. Earnings Scheduled For April 26, 2018Read the original story

    1 hr ago | Benzinga

    General Motors Company is projected to report quarterly earnings at $1.24 per share on revenue of $34.66 billion. Bristol-Myers Squibb Company is estimated to report quarterly earnings at $0.85 per share on revenue of $5.24 billion.

    Comment?

  3. New immunotherapy treatment for lung cancer dramatically improves survival, researchers reportRead the original story

    12 hrs ago | KurzweilAI.net

    Treatment cut in half the risk of dying or having the cancer worsen, compared to chemo alone, after nearly one year An immunotherapy treatment - one that boosts the immune system - has improved survival in people newly diagnosed with the most common form of lung cancer , according to an open-access study published in the New England Journal of Medicine . The study results were presented last Monday, April 16, at the annual American Association for Cancer Research conference in Chicago.

    Comment?

  4. Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to SellingRead the original story w/Photo

    16 hrs ago | TheStreet.com

    A lot of technical damage has been done to the charts and I am wondering if I failed to read the small print on the medicine bottle. Let's get some food before we look at the charts this afternoon.

    Comment?

  5. Autism Disorder and Treatment Industry Players Exploring New...Read the original story w/Photo

    22 hrs ago | SBWire

    The Global Autism Disorder and Treatment Industry have been segmented on the basis of treatment type, type and drugs. By type the market is segmented into the segments of Pervasive Developmental Disorder, Asperger Syndrome, and others.

    Comment?

  6. New Cancer Center Focuses on Safety and Access ControlsRead the original story w/Photo

    Yesterday | Building Operating Management

    On Friday, April 27, Bristol-Myers Squibb is officially welcoming the newest building to its Redwood City, Calif., research and development campus in Woodside Technology Park, celebrated with a ribbon-cutting ceremony. The newly-opened site serves as Bristol-Myers Squibb's biologics discovery center, focusing primarily on cancer immunotherapies - drugs that manipulate the immune system so that the body's own defensive network recognizes and attacks tumors.

    Comment?

  7. Bavarian Nordic (BVNRY) versus The Competition Head-To-Head ReviewRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    Bavarian Nordic is one of 89 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it weigh in compared to its rivals? We will compare Bavarian Nordic to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends. 49.3% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors.

    Comment?

  8. Monthly TCPA Digest - April 2018Read the original story w/Photo

    Tuesday | JD Supra

    We are pleased to present the latest edition of our Monthly TCPA Digest , providing insights and news related to the Telephone Consumer Protection Act . This month's issue examines a recent Illinois federal court ruling limiting class certification in a TCPA case to Illinois residents who received the fax at issue.

    Comment?

  9. Bristol-Myers And Exelixis Poise For Battle In Kidney Cancer - Who Will Emerge The Victor?Read the original story w/Photo

    Tuesday | Seeking Alpha

    In this article, I highlight a few considerations and pitfalls of comparing recently approved treatment options in first-line therapy. Note: Subscribers to the Total Pharma Tracker got an early look at this article, as well as access to an exclusive note offering my opinions on the end game for these companies.

    Comment?

  10. AstraZeneca flop a fresh blow to cancer immunotherapy combinationRead the original story w/Photo

    Tuesday | Channelnewsasia.com

    FILE PHOTO: A scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton, Britain, July 15, 2013. REUTERS/Stefan Wermuth/File Photo LONDON: The concept of combining two immunotherapy drugs to fight lung cancer: not so long ago one of the hottest ideas in cancer research: has suffered a fresh blow from the failure of an AstraZeneca clinical study.

    Comment?

  11. RPT-Amid drug price worries, earnings to test U.S. pharma, biotech sharesRead the original story w/Photo

    Tuesday | Reuters

    Major U.S. pharmaceutical and biotechnology companies, whose shares have been laggards even in a sluggish market, face a litmus test in the corporate earnings season as investors already gun-shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses. As a group, pharmaceutical stocks in the S&P 500 are down about 4 percent so far this year, while S&P biotech stocks are off about 6 percent.

    Comment?

  12. Capital Research Global Investors Raised Public Storage (Reit) (PSA)...Read the original story w/Photo

    Monday | Hill Country Times

    ... S.A. (DBVT) At $23.07 Forms Bottom; Strategic Wealth Advisors Groupinc Cut By $1.11 Million Its Bristol Myers Squibb Co (BMY) Holding DBV Technologies S.A. (DBVT) formed multiple bottom with $22.15 target or 4.00% below today's $23.07 share price. ...

    Comment?

  13. Bavarian Nordic (BVNRY) & Its Peers Head to Head ComparisonRead the original story w/Photo

    Monday Apr 23 | IntersportsWire

    Bavarian Nordic is one of 89 public companies in the "Biological products, except diagnostic" industry, but how does it weigh in compared to its competitors? We will compare Bavarian Nordic to similar businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations. Bavarian Nordic's competitors have higher revenue and earnings than Bavarian Nordic.

    Comment?

  14. Is It Time To Buy Philip Morris At Multi-Year Lows?Read the original story w/Photo

    Sunday Apr 22 | Seeking Alpha

    It's funny sometimes how the market or even fate can play games with you. It wasn't long ago that I was talking about raising cash and getting defensive because of macro threats that I was concerned about looming over the horizon.

    Comment?

  15. The No BS Plan Report, Week 10: Where The Reliable FalterRead the original story w/Photo

    Sunday Apr 22 | Seeking Alpha

    Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to another report from the No BS plan, a series keeping track of an experiment on equity investing discipline and how this might help you avoid becoming a dreaded bagholder in biotech stocks.

    Comment?

  16. Business RoundupRead the original story

    Sunday Apr 22 | Chemical & Engineering News

    Pixelligent has raised $7.6 million in additional funding. New backers include the Japanese materials firm Tokyo Ohka Kogyo.

    Comment?

  17. Bristol-Myers Squibb (BMY) Receives "Hold" Rating from CowenRead the original story w/Photo

    Saturday Apr 21 | IntersportsWire

    They currently have a $60.00 price objective on the biopharmaceutical company's stock. A number of other research firms have also commented on BMY.

    Comment?

  18. Bristol-Myers Squibb (BMY) Hits New 52-Week High and Low at $51.52Read the original story w/Photo

    Saturday Apr 21 | Daily Political

    Bristol-Myers Squibb hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $51.52 and last traded at $51.87, with a volume of 11562668 shares.

    Comment?

  19. Bristol-Myers Squibb (BMY) Price Target Cut to $47.00 by Analysts at BMO Capital MarketsRead the original story w/Photo

    Saturday Apr 21 | IntersportsWire

    BMO Capital Markets currently has an underperform rating on the biopharmaceutical company's stock. BMY has been the topic of a number of other research reports.

    Comment?

  20. Bank of America Lowers Bristol-Myers Squibb (BMY) Price Target to $61.00Read the original story w/Photo

    Friday Apr 20 | Daily Political

    Bank of America currently has a neutral rating on the biopharmaceutical company's stock. Several other equities analysts have also commented on the stock.

    Comment?